Liftstream is an executive search recruitment company in the life sciences sector
The UK has been seriously tackling the issue of diversity in the senior ranks of British business. The Davies Review, led by the charismatic but challenging Lord Mervyn Davies, pushed UK boards to get 25% of women on the boards of FTSE 100 companies. This triggered concerted action on the part of the nominated companies because they would be publicly measured, and reported.
HemaFlo Therapeutics, a private biotech company based in Carlsbad, Calif, has appointed Michael A. Martino as President, CEO and Board Director. Martino joined as President and CEO of Ambit Biosciences after its acquisition by Daiichi Sankyo in 2014.
Gurnet Point Capital, a Cambridge, MA-based US healthcare and life sciences investment firm, has founded Boston Pharmaceuticals, a fully integrated drug development company with a $600 million commitment. Christopher Viehbacher, the Managing Partner of Gurnet Point Capital and the former CEO of Sanofi, was appointed as Boston Pharmaceuticals’ Chairman. Robert Armstrong, the former head of external R&D at Chorus (Eli Lilly), was named CEO.
Thursday, December 3, 2015 from 4:00 PM to 7:30 PM (EST)
Biogen, Bio-9 Building, 300 Binney Street Cambridge, MA 02142 – View Map
Last month, Atlas Ventures investor and blogger Bruce Booth, penned a tremendous analysis of gender inequality in the biotech sector. I recommend you read it here. He made the case for a far greater level of women participation at the C-suite and Board level of biotechnology companies, and openly discussed the perceived shortcomings that Atlas Ventures has in this area of leadership appointments among its portfolio firms.
Just days after setting the terms for its pending IPO, Dimension Therapeutics, Inc., a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension’s Board of Directors. Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company’s Board is effective immediately.
In a continuation of a developing trend, two big-pharma executives left their cozy corner offices for the fast and wild biotech world. This year we have already seen a number of big names defect for the biotech world, the reasons for which were covered here. These latest appointments add further evidence to the fact that biotech has regained its form and now has pulling power.
Robert J. Perez, former Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joined its Board of Directors at Flex Pharma, a biotech which is developing therapies for exercise associate muscle cramps, nocturnal leg cramps, an neuromuscular related spasms.